Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema

NCT02734407 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Clinically Significant Diabetic Macular Edema

Interventions

PROCEDURE: Assigned Intervention
DRUG: aflibercept 2.0 mg

Sponsor

Retina-Vitreous Associates Medical Group